VitaNova Life Sciences Corporation

As of July 31, 2026, VitaNova Life Sciences Corporation carries a market capitalization of 19.84M, placing it among publicly traded companies globally. Its enterprise value stands at 18.24M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of July 31, 2026, VitaNova Life Sciences Corporation has 8.34M shares outstanding.

These figures are as of July 31, 2026. The price-to-sales ratio is 6.12, and the price-to-book ratio stands at 10.29.

These figures are as of July 31, 2026. The EV/Sales ratio of 5.62 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 18.24M versus a market cap of 19.84M, with the gap driven by net debt and cash on the balance sheet.

As of July 31, 2026, VitaNova Life Sciences Corporation maintains a current ratio of 7.13, meaning it holds 7.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended July 31, 2026, VitaNova Life Sciences Corporation posted a negative return on equity (ROE) of -6.02, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -5.09, reflecting losses generated across the asset base. The company generates approximately 810,803.75 in revenue per employee across its workforce of 4.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 15.28 indicates how many times VitaNova Life Sciences Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended July 31, 2026, VitaNova Life Sciences Corporation recorded 30,963.00 in income tax expense. The company reported a pretax loss of -83,141.00 and -114,104.00 in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, VitaNova Life Sciences Corporation's stock has declined approximately 70.67% over the past 52 weeks.

Over the twelve months ended July 31, 2026, VitaNova Life Sciences Corporation generated 3.24M in revenue and converted that into -114,104.00 in net income, yielding earnings per share of -0.01. EBITDA reached -86,121.00, while operating income came in at -86,121.00.

These figures are as of July 31, 2026. Total book value stands at 1.93M, with working capital of 1.91M providing operational flexibility.

VitaNova Life Sciences Corporation produced 557,561.00 in operating cash flow over the twelve months ended July 31, 2026.

Over the twelve months ended July 31, 2026, VitaNova Life Sciences Corporation posted a gross margin of 26.90, reflecting its pricing power and cost economics. The operating margin of -2.66 and net profit margin of -3.52 provide insight into operational efficiency.

These figures cover the twelve months ended July 31, 2026. Free cash flow yield stands at 2.81, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt.

VitaNova Life Sciences Corporation's most recent stock split took place on January 27, 2026 with a 3:1 split ratio.

As of July 31, 2026, VitaNova Life Sciences Corporation has an Altman Z-Score of 40.99, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.